FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered strongerthanexpected firstquarter performance which reflects our disciplined execution, including accelerated commercial initiatives and broadbased growth across key end markets," said Tom Polen, chairman, CEO and president of BD. "Today, we expect to complete the ...

Becton, Dickinson and Company (NYSE:BDX) is included among the Dividend Growth Stocks: 25 Aristocrats. Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX) On January 28, Piper Sandler analyst Jason Bednar lifted Becton, Dickinson and Company (NYSE:BDX)’s price recommendation to $205 from $190. The analyst maintained a Neutral rating. The firm pointed to changes in how BD reports its business units starting in Q1 2026 and said it is updating its financial model to align with the ...

Core Insights - BD (Becton, Dickinson and Company) is investing $110 million to expand its production of prefillable syringes in Columbus, Nebraska, which will create approximately 120 new jobs and enhance supply resilience within its Pharmaceutical Systems portfolio [1][4]. Investment Details - The investment includes $100 million for establishing BD Neopak™ Glass Prefillable Syringe production, with supply expected to begin in mid-2026 [4]. - An additional $10 million will be allocated to enhance cannula manufacturing capabilities at the Columbus site [4]. - This expansion follows a previous investment of over $35 million to expand prefilled flush syringe manufacturing, which will add approximately 50 new jobs [5]. Product Features - The BD Neopak™ Glass Prefillable Syringe platform is designed to meet the complex needs of biologics and combination products, available in 1 mL and 2.25 mL formats [2]. - It supports high viscosity formulations and is compatible with various drug-container integrations, facilitating seamless use with autoinjectors for patient-centric drug delivery [2]. Strategic Importance - This investment is part of BD's long-term growth strategy to strengthen its American manufacturing footprint and support U.S.-based drug delivery innovation [3][6]. - The move aims to build a more resilient pharmaceutical supply chain in the U.S., ensuring continuity and speed to market for injectable therapies as demand for biologics rises [6][7]. Company Commitment - BD is committed to investing over $2.5 billion in U.S. manufacturing capabilities over the next five years, reinforcing its position as the largest medical device manufacturer in the United States [5].